GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allena Pharmaceuticals Inc (OTCPK:ALNAQ) » Definitions » Owner Earnings per Share (TTM)

Allena Pharmaceuticals (Allena Pharmaceuticals) Owner Earnings per Share (TTM) : 0.00 (As of Jun. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Allena Pharmaceuticals Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Allena Pharmaceuticals's Owner Earnings per Share (TTM) ended in Jun. 2022 was $0.00. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Allena Pharmaceuticals's Owner Earnings per Share (TTM) or its related term are showing as below:



ALNAQ's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.12
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Allena Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Jun. 2022 was $-0.08. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $-0.49. It's PE Ratio ratio for today is At Loss.

Allena Pharmaceuticals's EPS without NRI for the three months ended in Jun. 2022 was $-0.07. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2022 was $-0.48. It's PE Ratio without NRI ratio for today is At Loss.


Allena Pharmaceuticals Owner Earnings per Share (TTM) Historical Data

The historical data trend for Allena Pharmaceuticals's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allena Pharmaceuticals Owner Earnings per Share (TTM) Chart

Allena Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial - - - -0.79 -0.61

Allena Pharmaceuticals Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.67 -0.59 -0.61 -0.67 -0.54

Competitive Comparison of Allena Pharmaceuticals's Owner Earnings per Share (TTM)

For the Biotechnology subindustry, Allena Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allena Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allena Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Allena Pharmaceuticals's Price-to-Owner-Earnings falls into.



Allena Pharmaceuticals Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Allena Pharmaceuticals's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -43.30
Depreciation, Depletion and Amortization 0.46
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 0.37
Change In Working Capital -10.91
Shares Outstanding (Diluted Average) 100.62

1. Start with "Net Income" from income statement. Allena Pharmaceuticals's Net Income for the trailing twelve months (TTM) ended in Jun. 2022 was $-43.30 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Allena Pharmaceuticals's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Jun. 2022 was $0.46 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Allena Pharmaceuticals's Change In Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2022 was $0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $0.37 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Allena Pharmaceuticals's 5-Year Average Maintenance Capital Expenditure = $0.37 Mil

5. "Change In Working Capital" is from cashflow statement. Allena Pharmaceuticals's Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2022 was $-10.91 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Allena Pharmaceuticals's Shares Outstanding (Diluted Average) for the months ended in Jun. 2022 was 100.624 Mil.

Allena Pharmaceuticals's Onwer Earnings Per Share for Jun. 2022 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -43.303 +0.461+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-0.36933333333333+-10.905)/100.624
=0.00

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=1.0E-6/0.00
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Allena Pharmaceuticals Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Allena Pharmaceuticals's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Allena Pharmaceuticals (Allena Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
One Newton Executive Park, Suite 202, Newton, MA, USA, 02462
Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.
Executives
Louis Md Brenner officer: See Remarks RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02140
Mark J. Fitzpatrick director 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Richard D Katz officer: Chief Financial Officer 4505 EMPEROR BOULEVARD, SUITE 300, DURHAM NC 27703
Edward Wholihan officer: Chief Financial Officer C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Ann Calby Miller director C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Allene M. Diaz director C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Hack Andrew A. F. director 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Bessemer Venture Partners Vii L.p. 10 percent owner C/O BESSEMER VENTURE PARTNERS, 1865 PALMER AVENUE, LARCHMONT NY 10538
Hbm Biocapital Ii Lp 10 percent owner 11-15 SEATON PLACE, ST. HELIER Y9 JE4 0QH
James N Topper director, 10 percent owner 550 HAMILTON AVENUE, SUITE 100, PALO ALTO CA 94301
Fhm Vi, L.l.c. 10 percent owner 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Robert I Tepper director, 10 percent owner 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Third Rock Ventures Ii, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Robert Alexander director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Alexey L Margolin director, officer: Chief Executive Officer C/O ALTUS PHARMACEUTICALS INC., 125 SIDNEY STREET, CAMBRIDGE MA 02139

Allena Pharmaceuticals (Allena Pharmaceuticals) Headlines

From GuruFocus